Perioperative cardiac risk stratification and modification in abdominal aortic aneurysm repair

Acta Chir Belg. 2006 Jul-Aug;106(4):361-6. doi: 10.1080/00015458.2006.11679908.

Abstract

Cardiovascular complications are important causes of morbidity and mortality following vascular surgery. Adequate preoperative risk assessment and perioperative management may modify postoperative mortality and morbidity and improve long-term prognosis. The objective of this review is to examine the present day knowledge regarding the preoperative evaluation and perioperative management of patients undergoing noncardiac surgery, focusing specifically on abdominal aortic aneurysm (AAA) repair. Clinical markers combined with ECG and surgical risk assessment can effectively divide patients in a truly low-risk, intermediate and high-risk population. Low-risk patients can probably be operated on without additional cardiac testing. Notably, due to the surgical risk, AAA patients are never low-risk patients. Intermediate-risk and high-risk patients are referred for cardiac testing to exclude extensive stress induced myocardial ischemia, as beta-blockers provide insufficient myocardial protection in this case and preoperative coronary revascularization might be considered. Whether patients at intermediate risk without ischemic heart disease should be treated with statins and/or beta-blockers is still controversial. In high-risk patients, it is strongly advised to administer beta-blockers with heart rate determined dose adjustment, while the effects of preoperative revascularization remain subject to debate.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aortic Aneurysm, Abdominal / surgery*
  • Biomarkers / analysis
  • Electrocardiography
  • Heart Diseases / prevention & control*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Perioperative Care*
  • Postoperative Complications / prevention & control*
  • Risk Assessment
  • Risk Factors

Substances

  • Adrenergic beta-Antagonists
  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors